US EditionPublished • loading... • Updated
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Summary by The Toronto Star
9 Articles
9 Articles
St Catharines Standard+8 Reposted by 8 other sources
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline,…
·Welland, Canada
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left7Leaning Right2Center0Last UpdatedBias Distribution78% Left
Bias Distribution
- 78% of the sources lean Left
78% Left
L 78%
R 22%
Factuality
To view factuality data please Upgrade to Premium
